UCC Student Medical Journal Vol. 3 (2023)

Permanent URI for this collection

https://hdl.handle.net/10468/16582

Browse

Recent Submissions

Now showing 1 - 5 of 10
  • Thumbnail Image
    Item
    UCC Student Medical Journal 3rd Edition
    (UCC Medical Research and Technology Society, 2023) Zagoneanu, Adina Elena
    UCC Student Medical Journal 3rd Edition
  • Thumbnail Image
    Item
    Lille Erasmus exchange
    (UCC Medical Research and Technology Society, 2023) Dablouk, Lena
    Lille Erasmus exchange
  • Thumbnail Image
    Item
    Religiosity and psychosis
    (UCC Medical Research and Technology Society, 2023) Malakhveitchouk, Anton
    Religion and spirituality (RS) have been integral aspects throughout human history, possibly being observed as far back as 500,000 years ago in the ritual treatment of skulls during the palaeolithic period. Today, despite the growth in relatively secular societies, almost 90% of the world has some RS affiliation. Interestingly enough, mental health has historically been interlinked with RS. Family and adoption studies show that a family history of psychosis is correlated with intense interest in RS. Furthermore, the association between Postictal psychosis, a common complication of epilepsy, with religiosity is well documented. It is conceivable that this association led to epilepsy being historically linked with the divine, demonic and supernatural. In fact, there is ample evidence to suggest that many historic religious figures had epilepsy and psychosis. In clinical practice - and in broader society - the incidence of religiosity in epilepsy patients is likely underestimated. While postictal psychosis symptoms range in RS intensity, it is not uncommon for patients to have severe RS delusions and even convert after episodes.
  • Thumbnail Image
    Item
    Behavioral addictions and psychosis
    (UCC Medical Research and Technology Society, 2023) Aamer, Kashaf
    M.K* is a 27-year-old, single, unemployed male that was driven to the Emergency Department by his foster father, four weeks ago with first episode of psychiatric symptoms of tactile hallucinations, auditory hallucinations of male and female voices making inappropriate sexual comments about him, persecutory delusions and delusions of control for the past five days. M.K is a daily cannabis user of 0.5-1g use for the past 2 years and has 5.5 pack year smoking history. M.K also reports having a pornography and masturbation addiction for 2 years with marked intrusive thoughts of sexual nature the past week. M.K has no medical or psychiatric history. Recent stressor was moving out of foster father’s house 8 days ago. The symptoms led to significant impact at work which he has quit since then. On presentation, M. K showed partial insight into his third person running commentary hallucinations but believed adamantly that he was being watched, followed and controlled. He reported hearing his female neighbour stating that he has sexual interest in animals and later heard his manager making pedophilic allegations on him. M.K was so distressed, he quit work and isolated himself in his room. He reported poor concentration and lack of appetite for the past week. M.K describes his baseline mood to have “always been not the greatest” and denied anhedonia, fatigue, or sleep changes. He denied thoughts of self- harm, harm to others or suicidal ideation. Four weeks following inpatient, referral to HBCT and cannabis abstinence has shown improvement in psychiatric symptoms with absence of hallucinations, however, there has been increased symptoms of anxiety with “panic attacks”. M.K’s biological mother is reported to have history of substance misuse and sister with depressive symptoms. He continues to withdraw from society with increased time spent indoors gaming and shows emotional dependence on foster father.
  • Thumbnail Image
    Item
    Immunogenicity and safety of Cervarix HPV-16/18 AS04-adjuvant vaccine against HPV induced cervical cancer in women (15+ years)
    (UCC Medical Research and Technology Society, 2023) Zagoneanu, Adina Elena
    Background: The incidence of cervical cancer has decreased by over 50% from the mid-1970s to the mid-2000s. This is due in part to an increase in screening, which can identify cervical changes before they turn cancerous. Decreasing incidence rates in young women may be due to the use of the HPV vaccine. There are currently three types of HPV vaccines on the market: bivalent, quadrivalent and nine-valent HPV vaccines. These are administered in three-doses to both sexes from age 15 upwards to prevent HPV infection. Many medical systems support the vaccination of teenage girls and boys with HPV vaccines during their secondary school years in order to reduce the incidence of HPV-related cervical cancer in women. Despite the discovery of the link between HPV and cervical cancer in 1985, the beginning of vaccine production in 2002, and promotion of screening procedures since the 1960’s, cervical cancer is still the fourth most common cancer in women worldwide today. Objective: This review aims to analyse the immunogenicity and safety of Cervarix®, also known as HPV-16/18 AS04-adjuvant vaccine, in women (15+ years) against cervical cancer. Methods: The literature review analysing the effectiveness and immunogenicity of HPV-16/18 AS04-ADJUVANTED Vaccine against cervical cancer, was conducted by using two main databases: EbescoHost (Medline and Academic Search) and PubMed. Advanced searches were conducted using specific key words, various filters and Boolean operators ‘OR’ and ‘AND’ to find the most suitable literature. This process resulted in over 100 results. From this cohort, clinical trials were selected in accordance with the specific inclusion and exclusion criteria determined for the review. After duplicates from both databases were removed, the studies were assessed in order or title, population and objective relevance, and the top 10 most relevant articles to the title of the literature review, were selected for the literature review. Results: The 10 clinical trials selected all obtained a minimum of 10 out of the 11 CASP requirements indicating good study quality. All 10 studies were successful in proving the immunogenicity and safety of the HPV-16/18 AS04-adjuvant vaccine in protecting women 15+ (15-55 years) from developing HPV-induced cervical cancer [15, 16, 17, 18, 19, 20, 21, 22, 23, 24]. This confers that vaccination against HPV-16/18 virus proves to be effective in preventing HPV-induced CIN and cervical cancer and is a safe to administer vaccine.